CalciMedica enrolls last patient in Phase 2b CARPO trial of Auxora

CalciMedica announced that the last patient has been enrolled in its Phase 2b CARPO trial of Auxora in acute pancreatitis, or AP. Auxora is a potent and selective small molecule inhibitor of Orai1-containing CRAC channels that is being developed for use in patients with acute inflammatory and immunologic illnesses. CARPO is an international, randomized, double-blind, placebo-controlled, dose-ranging trial intended to establish Auxora’s dose-response and efficacy in AP with accompanying systemic inflammatory response syndrome. The trial reached its target enrollment of 216. These patients have been randomized into four groups to receive either 2.0 mg/kg, 1.0 mg/kg or 0.5 mg/kg of Auxora or a dose of placebo intravenously every 24 hours for a total of three doses. CARPO protocol requires that treatment and observation of patients continue for 30 days, and the company plans to report topline data later this quarter.